Publication: Purification of human hemopoietic stem cells for transplantation in Thailand
Issued Date
2000-06-01
Resource Type
ISSN
0125877X
Other identifier(s)
2-s2.0-0033926467
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.18, No.2 (2000), 85-92
Suggested Citation
Chirayu Udomsakdi-Auewarakul, Yaowaluk U-Pratya, Viroje Chongkolwatana, Voravarn S. Tanphaichitr, Kovit Pattanapanyasat, Surapol Issaragrisil Purification of human hemopoietic stem cells for transplantation in Thailand. Asian Pacific Journal of Allergy and Immunology. Vol.18, No.2 (2000), 85-92. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25984
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Purification of human hemopoietic stem cells for transplantation in Thailand
Other Contributor(s)
Abstract
Stem cell transplantation (SCT) has become the therapy of choice for many hematologic and immunologic disorders. At present, only 25% of patients have suitable HLA-identical donors. In an attempt to increase the donor pool for SCT in Thailand and Southeast Asia, we developed a program whereby parents and mismatched siblings can be used as donors. In this preliminary study, after granulocyte-colony-stimulating factor (G-CSF) was given to adult donors, peripheral blood stem cells (PBSC) were collected and CD34+ cells purified using a CliniMACS immunomagnetic device (Miltenyi Biotec, Germany). In seven experiments, purified CD34+ cells could be obtained from G-CSF-stimulated PBSC in large numbers (1.71 ± 0.19 x 108), with high purity (93 ± 2.4%) and excellent recovery (64.28%-85.62%). Immune reactive T and NK cells were adequately depleted to less than 0.2%. The purification procedure can be completed within 3 hours. In conclusion, a clinical stem cell purification program using this novel device is now established in Thailand and for the first time in Southeast Asia. This should allow further development of advanced SCT therapy including haploidentical and mismatched CD34+ SCT for patients lacking HLA-identical donors in this region.